Status:
COMPLETED
Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL
Lead Sponsor:
Samsung Medical Center
Conditions:
Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
Eligibility:
All Genders
Brief Summary
In case of relapsed or refractory ALK-negative ALCL patients, high-dosage chemotherapy/ stem cell transplantation is a universal salvage option for patients with sensitivity to anti-cancer treatment a...
Eligibility Criteria
Inclusion
- Any patient subject to one of the following at the start of treatment with BrentuximabVedotin:
- Any patient planning to administer BrentuximabVedotin to treat the target disease;
- Any patient administering BrentuximabVedotin to treat the target disease;
- Any patient tracing BrentuximabVedotin after treating the target disease; or
- Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin.
Exclusion
- If conditions for target diseases are not met.
- If conditions for target patients are not met.
- If patients do not give written consent to participate in study.
Key Trial Info
Start Date :
November 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03766516
Start Date
November 1 2018
End Date
December 30 2021
Last Update
February 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, Gangnam-Gu, South Korea, 06351